celecoxib has been researched along with concanavalin a in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Coles, M; Hood, KC; Shafer, LR; Talmadge, JE; Toth, B; Zobel, LC | 1 |
| El-Sheakh, AR; Khaleel, A; Suddek, GM | 1 |
2 other study(ies) available for celecoxib and concanavalin a
| Article | Year |
|---|---|
Chemoprevention by cyclooxygenase-2 inhibition reduces immature myeloid suppressor cell expansion.
Topics: 1,2-Dimethylhydrazine; Adjuvants, Immunologic; Animals; Anticarcinogenic Agents; Arginase; Breast Neoplasms; Carcinogens; CD4-Positive T-Lymphocytes; Celecoxib; Cell Proliferation; Concanavalin A; Cyclooxygenase 2 Inhibitors; Female; Intestinal Neoplasms; Membrane Proteins; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Nitric Oxide Synthase Type II; Pyrazoles; RNA, Messenger; Spleen; Sulfonamides | 2007 |
Celecoxib abrogates concanavalin A-induced hepatitis in mice: Possible involvement of Nrf2/HO-1, JNK signaling pathways and COX-2 expression.
Topics: Animals; Antioxidants; Beclin-1; Caspase 3; Celecoxib; Concanavalin A; Cyclooxygenase 2; Heme Oxygenase-1; Hepatitis, Autoimmune; Humans; Liver; Male; MAP Kinase Signaling System; Mice; NF-E2-Related Factor 2; Proto-Oncogene Proteins c-akt | 2023 |